Skip to main content

Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Charact

Social Author Name
Dr. John Cush
Tweet Content
Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study https://t.co/3vkUQnpm9F https://t.co/h5OijjETUk

Sensor-engineered glove evaluates hand function in RA Dr. David Liew discusses abstract 0904 at ACR22 Convergence. Abs

Social Author Name
Dr. John Cush
Tweet Content
Sensor-engineered glove evaluates hand function in RA Dr. David Liew discusses abstract 0904 at ACR22 Convergence. Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis https://t.co/e5VCOC56BC https://t.co/vfuVWMrqSj

Netherlands study of 220 consecutive inflammatory arthritis pts enrolled in electronic remote telehealth monitoring show

Social Author Name
Dr. John Cush
Tweet Content
Netherlands study of 220 consecutive inflammatory arthritis pts enrolled in electronic remote telehealth monitoring showed that 141 (64%) dropped out, with a median dropout at 17 wks ( moreso in women). Why? Simple is not alway simple... https://t.co/nziKil4vas https://t.co/oyyulMnIu1

National cohort of 20–39-yr old men - among ~1.3 million, 18,473 Dx w/ gout (incidence 3.36/1,000 PY). Developing meta

Social Author Name
Dr. John Cush
Tweet Content
National cohort of 20–39-yr old men - among ~1.3 million, 18,473 Dx w/ gout (incidence 3.36/1,000 PY). Developing metabolic syndr doubled #gout risk (aHR 2.31); MetS at all visits had 4x risk (aHR 3.82) & MetS recovery reduced gout risk by 59% https://t.co/bLmf1AL5VI https://t.co/8c47zk6vqu

Top 10 Pharma Revenues 2021: 1 J&J $93.77 billion (USD) 2 Pfizer $81.29 B 3 Roche $68.7 B 4 AbbVie S$56.2 B 5 No

Social Author Name
Dr. John Cush
Tweet Content
Top 10 Pharma Revenues 2021: 1 J&J $93.77 billion (USD) 2 Pfizer $81.29 B 3 Roche $68.7 B 4 AbbVie S$56.2 B 5 Novartis $51.63 B 6 Merck $48.7 B 7 BMS $46.4 B 8 GSK $43.57 B 9. Sanofi $44.67 B 10. AstraZeneca $37.47 B https://t.co/ptFAyk4S5S https://t.co/cCtPboI53x

Goofy or Novel: "How gravity may cause irritable bowel syndrome". A hypothesis, published in the American Journal of Gas

Social Author Name
Dr. John Cush
Tweet Content
Goofy or Novel: "How gravity may cause irritable bowel syndrome". A hypothesis, published in the American Journal of Gastroenterology, describes how the intestines, spine, heart, nerves and brain evolved to manage gravity. https://t.co/lLyAkruyyy? https://t.co/TJH8Du8rm6

Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines Following the 2016 American Academy of Ophthalmology Guide

Social Author Name
Dr. John Cush
Tweet Content
Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines Following the 2016 American Academy of Ophthalmology Guidelines, rheums have dutifully reduced the dose of HCQ taken by patients with SLE to some number south of 5mg/kg per day. https://t.co/iToRttwPbC https://t.co/REpWkI7vC0

A Multidimensional Approach in the Management of Axial Spondylarthritis Abstract 1510 by Jones et al studied the effec

Social Author Name
Dr. John Cush
Tweet Content
A Multidimensional Approach in the Management of Axial Spondylarthritis Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis. https://t.co/Y5syU5cX6Y https://t.co/PO7TZ3ZBOo

Visit our podcast channel and listen to experts from the #SLEEducatorsNetwork discuss how biologic therapies could help

Social Author Name
Dr. John Cush
Tweet Content
Visit our podcast channel and listen to experts from the #SLEEducatorsNetwork discuss how biologic therapies could help address key unmet needs in #lupus, and how clinicians can identify the most appropriate patients for biologics. #SponsoredbyGSKUSMA https://t.co/zYB48YvNDC https://t.co/gL67G5jQv8

Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx i

Social Author Name
Dr. John Cush
Tweet Content
Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx in 35%. Findings: livedo racemosa (45%), necrosis/ulcers (42%), splinter hemorrhages (29%), distal edema (23%), purpura (14%). https://t.co/zFsPUdo4Wb https://t.co/rEN4yfoP9h
Subscribe to
×